Moderna Says FDA Refuses To Review Its Application for Experimental Flu Shot

Source: Slashdot

FDA Refuses to Review Moderna’s Experimental Flu Shot Application

The Food and Drug Administration (FDA) has declined to begin a review of Moderna’s application for its experimental flu vaccine, mRNA‑1010, according to a report shared by an anonymous reader.

Background

• Moderna announced the flu shot candidate, mRNA‑1010, entered Phase 3 trials earlier this year.
• Positive Phase 3 data were reported last year, meeting all trial endpoints.
• The company has positioned the stand‑alone flu vaccine as a stepping stone toward a combined influenza‑COVID‑19 vaccine.

FDA Decision

• The FDA’s refusal to start the review is described as a shift from earlier feedback the agency gave before Moderna submitted the application and began Phase 3 trials.
• The agency did not cite specific safety or efficacy concerns.
• Instead, the FDA objected to the study design, despite having previously approved that design.

Moderna’s Response

• Moderna has requested a meeting with the FDA to “understand the path forward.”
• The company emphasized that the FDA’s action does not affect its 2026 financial guidance.

Implications

• The decision is seen as part of broader regulatory tightening under the current administration.
• It may delay the potential launch of the flu vaccine and the subsequent combination vaccine strategy.

Read more of this story at Slashdot